Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11906-018-0840-8 http://scihub22266oqcxt.onion/10.1007/s11906-018-0840-8 C5942348!5942348!29744599     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29744599.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Curr+Hypertens+Rep 2018 ; 20 (5): ä Nephropedia Template TP {{tp|p=29744599|t=2018. Endovascular Baroreflex Amplification for Resistant Hypertension |pdf=|usr=}}{{29744599}} gab.com Text Endovascular Baroreflex Amplification for Resistant Hypertension JO: Curr Hypertens Rep http://www.kidney.de/pget.php?&tw=1&pmid=29744599 #FOAvip Purpose of review: Most hypertension devices have been designed to interrupt or modify the sympathetic nervous system, which seems to be unbalanced in hypertension. Carotid baroreceptors play a pivotal role in maintaining adrenergic balance via a direct feedback interface and would be an exceptional target for intervention. The purpose of this review is to define the role of the baroreceptor in hypertension, to examine device-based therapies targeting the baroreflex and to explore future promises of endovascular baroreflex amplification (EBA). Recent findings: In the last two decades, two therapeutic strategies targeting the carotid baroreceptor have evolved: baroreflex activation therapy (BAT) and EBA. Both therapies enhance baroreceptor activity, either directly by electrical stimulation or indirectly by changing the geometric shape of the carotid sinus and increasing pulsatile wall strain. Summary: By showing a significant, sympathetic inhibition-mediated effect on blood pressure, BAT has laid the foundation for baroreflex-targeting therapies for resistant hypertension. EBA is a less invasive therapy with promising first-in-man study results. Ongoing randomized sham-controlled trials are needed to better understand efficacy, durability, and long-term safety and define phenotypes that may most benefit from this treatment. Electronic supplementary material: The online version of this article (10.1007/s11906-018-0840-8) contains supplementary material, which is available to authorized users. Twit Text FOAVip Endovascular Baroreflex Amplification for Resistant Hypertension ????Curr Hypertens Rep http://www.kidney.de/pget.php?&tw=1&pmid=29744599 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29744599 #FOAvip English Wikipedia <ref>{{Cite pmid|29744599}}</ref> Endovascular Baroreflex Amplification for Resistant Hypertension #MMPMID29744599 van Kleef MEAM; Bates MC; Spiering W Curr Hypertens Rep 2018[]; 20 (5): ä PMID29744599show ga Purpose of review: Most hypertension devices have been designed to interrupt or modify the sympathetic nervous system, which seems to be unbalanced in hypertension. Carotid baroreceptors play a pivotal role in maintaining adrenergic balance via a direct feedback interface and would be an exceptional target for intervention. The purpose of this review is to define the role of the baroreceptor in hypertension, to examine device-based therapies targeting the baroreflex and to explore future promises of endovascular baroreflex amplification (EBA). Recent findings: In the last two decades, two therapeutic strategies targeting the carotid baroreceptor have evolved: baroreflex activation therapy (BAT) and EBA. Both therapies enhance baroreceptor activity, either directly by electrical stimulation or indirectly by changing the geometric shape of the carotid sinus and increasing pulsatile wall strain. Summary: By showing a significant, sympathetic inhibition-mediated effect on blood pressure, BAT has laid the foundation for baroreflex-targeting therapies for resistant hypertension. EBA is a less invasive therapy with promising first-in-man study results. Ongoing randomized sham-controlled trials are needed to better understand efficacy, durability, and long-term safety and define phenotypes that may most benefit from this treatment. Electronic supplementary material: The online version of this article (10.1007/s11906-018-0840-8) contains supplementary material, which is available to authorized users. äEndovascular Baroreflex Amplification for Resistant Hypertension (epmc).pdf DeepDyve Pubget Overpricing